TransMedics Group (NASDAQ:TMDX) Sees Unusually-High Trading Volume – Should You Buy?

by · The Markets Daily

Shares of TransMedics Group, Inc. (NASDAQ:TMDX – Get Free Report) saw unusually-strong trading volume on Thursday . Approximately 976,788 shares traded hands during trading, a decline of 8% from the previous session’s volume of 1,057,560 shares.The stock last traded at $66.92 and had previously closed at $62.35.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $75.00 price target (down from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Canaccord Genuity Group dropped their price target on TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research note on Wednesday, November 20th. TD Cowen dropped their target price on TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. Oppenheimer reissued an “outperform” rating and issued a $125.00 price objective on shares of TransMedics Group in a report on Tuesday, December 3rd. Finally, Robert W. Baird cut their price objective on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research report on Wednesday, December 11th. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $122.70.

View Our Latest Stock Analysis on TransMedics Group

TransMedics Group Stock Performance

The company has a market capitalization of $2.25 billion, a price-to-earnings ratio of 71.42 and a beta of 2.06. The stock’s fifty day simple moving average is $78.06 and its 200-day simple moving average is $124.46. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42.

TransMedics Group (NASDAQ:TMDX – Get Free Report) last released its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm had revenue of $108.76 million for the quarter, compared to analysts’ expectations of $115.00 million. During the same period last year, the firm posted ($0.12) earnings per share. TransMedics Group’s revenue for the quarter was up 63.7% on a year-over-year basis. Analysts predict that TransMedics Group, Inc. will post 1 EPS for the current year.

Insider Activity at TransMedics Group

In other TransMedics Group news, Director Edward M. Basile sold 6,750 shares of the company’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total transaction of $563,962.50. Following the completion of the sale, the director now directly owns 732 shares of the company’s stock, valued at $61,158.60. This represents a 90.22 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Tamer I. Khayal sold 1,084 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total value of $93,657.60. Following the transaction, the insider now directly owns 20,843 shares of the company’s stock, valued at approximately $1,800,835.20. This trade represents a 4.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 16,459 shares of company stock valued at $1,802,244 over the last ninety days. Insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

A number of institutional investors have recently modified their holdings of the company. Driehaus Capital Management LLC increased its stake in shares of TransMedics Group by 15.8% during the 2nd quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock valued at $223,832,000 after acquiring an additional 202,867 shares during the last quarter. Principal Financial Group Inc. raised its position in shares of TransMedics Group by 260.1% in the 3rd quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock worth $31,759,000 after buying an additional 146,115 shares during the period. Hood River Capital Management LLC acquired a new position in TransMedics Group during the second quarter valued at approximately $18,854,000. Canada Pension Plan Investment Board purchased a new position in TransMedics Group in the 2nd quarter worth approximately $16,086,000. Finally, Public Sector Pension Investment Board purchased a new position in shares of TransMedics Group in the third quarter valued at $11,079,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

About TransMedics Group

(Get Free Report)

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Featured Articles